Leaflet MUCOSOLVAN MAX 75mg prolonged release capsules


Indicated for: respiratory disorders with viscous secretions

Substance: ambroxol (mucolytic)

ATC: R05CB06 (Respiratory system | Expectorants, excl. combinations with cough suppressants | Mucolytics)

Ambroxol is a mucolytic agent used to treat respiratory conditions characterized by excessive production of viscous mucus. It is indicated for acute and chronic bronchitis, asthma, chronic obstructive pulmonary disease (COPD), and other lung conditions involving difficulty in mucus clearance.

Ambroxol works by reducing mucus viscosity and stimulating the activity of cilia in the airways, facilitating expectoration. It is effective in relieving productive cough and improving breathing.

Additionally, ambroxol has anti-inflammatory and antioxidant properties, making it useful in reducing airway inflammation. In some cases, it is also used to alleviate sore throat pain due to its local anesthetic effect.

It is available in the form of tablets, syrup, oral solution, or inhalation, and is well-tolerated by most patients. Side effects are rare and may include nausea, stomach discomfort, or mild allergic reactions.

General data about MUCOSOLVAN MAX 75mg

  • Substance: ambroxol
  • Date of last drug list: 01-04-2022
  • Commercial code: W68459001
  • Concentration: 75mg
  • Pharmaceutical form: prolonged release capsules
  • Quantity: 10
  • Product type: original
  • Prescription restrictions: OTC - Over the Counter = medicines that do not require a prescription.

Marketing authorisation

  • Manufacturer: DELPHARM RHEIMS - FRANTA
  • Holder: OPELLA HEALTHCARE ROMANIA SRL - ROMANIA
  • Number: 7323/2015/01
  • Shelf life: 3 years

Concentrations available for ambroxol

  • 0.3%
  • 0.75%
  • 15mg
  • 15mg/5ml
  • 15mg/ml
  • 20mg
  • 30mg
  • 30mg/5ml
  • 3mg/ml
  • 50mg/g
  • 60mg
  • 6mg/ml
  • 7.5mg/ml
  • 75mg